Strategic Focus Tosk is targeting oncology with a dual approach: mitigating chemotherapy side effects and blocking KRAS-driven cancers, presenting opportunities to partner on combination therapies, supportive care products, or companion diagnostics to expand patient eligibility and treatment tolerability.

Clinical Momentum TK-90 has progressed to Phase 2 in head and neck cancer patients receiving high-dose chemotherapy, signaling potential near-term milestones and collaboration windows for oncology-focused CROs, contract manufacturing, or phase-appropriate clinical service providers.

Advisory Strength Recent additions to scientific and medical advisory boards indicate active efforts to bolster expertise and credibility, suggesting openings for strategic partner alignment, advisory roles with co-development discussions, or sponsored research engagements.

Funding Signals Early-stage funding and a sizable NCI grant demonstrate validated interest and financial backing for their oncology programs, presenting opportunities for investors, grant-focused partnerships, or sponsored clinical research arrangements.

Market Readiness With revenue in the low to mid range and ongoing development of multiple cancer-focused therapies, there is potential for early access programs, regional distribution partnerships, and services around clinical trial logistics, patient access, and therapy enabling technologies.